Ollin Biosciences Announces $330M Series B to Accelerate OLN324 for DME and Wet AMD
AUSTIN, TX, June 24, 2026 Ollin Biosciences has announced the successful completion of an oversubscribed $330 million Series B...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
AUSTIN, TX, June 24, 2026 Ollin Biosciences has announced the successful completion of an oversubscribed $330 million Series B...
